Andong-si and SK Plasma Sign MOU to Expand Blood Product Pharmaceutical Manufacturing Plant
An Additional 24.2 Billion Won Invested by 2022 in Existing Gyeongbuk Bio Industrial Complex Factories
[Asia Economy Yeongnam Reporting Headquarters Reporter Park Dong-wook] On the afternoon of the 8th, Andong City in Gyeongbuk signed a Memorandum of Understanding (MOU) with SK Plasma Co., Ltd. (CEO Kim Yoon-ho) at City Hall for investment to expand the blood product pharmaceutical manufacturing plant.
SK Plasma, which spun off from SK Chemicals Co., Ltd. in 2015, built a factory capable of producing 600,000 liters of blood product pharmaceuticals annually on a 31,586㎡ site within the Gyeongbuk Bio General Industrial Complex in 2018. Since then, to meet the continuous increase in demand, it plans to invest an additional 24.2 billion KRW by 2022 to expand production facilities and infrastructure at the existing site.
Through this investment, SK Plasma is expected to contribute to job creation and increase local residents' income by hiring approximately 55 new employees, according to Andong City.
Hot Picks Today
After Topping 8,000 Instead of Hitting 10,000... KOSPI Plunges—When Will It Rebound?
- "Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- [Breaking] Court Rules Against Samsung Electronics Union...1 Billion Won per Day Penalty for Exceeding Strike Scope
- Six Economic Organizations Urge Withdrawal of Samsung Electronics Strike Plan...Warn of National Loss of Opportunity
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
An official from Andong City stated, "Amid difficult economic conditions, we expect this MOU signing to bring great vitality to the local economy, and we will seek various support measures to ensure the successful promotion of the investment."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
